Zymeworks Inc. (NYSE:ZYME – Get Free Report) Director Ecor1 Capital, Llc acquired 58,306 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The stock was purchased at an average cost of $12.64 per share, for a total transaction of $736,987.84. Following the acquisition, the director now owns 17,030,604 shares in the company, valued at approximately $215,266,834.56. This trade represents a 0.34 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Monday, March 17th, Ecor1 Capital, Llc acquired 56,277 shares of Zymeworks stock. The stock was purchased at an average cost of $12.23 per share, for a total transaction of $688,267.71.
- On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was purchased at an average cost of $12.48 per share, for a total transaction of $5,845,082.88.
- On Tuesday, March 11th, Ecor1 Capital, Llc acquired 320,690 shares of Zymeworks stock. The stock was purchased at an average cost of $11.49 per share, for a total transaction of $3,684,728.10.
- On Friday, January 17th, Ecor1 Capital, Llc acquired 19,748 shares of Zymeworks stock. The stock was purchased at an average cost of $13.87 per share, for a total transaction of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc acquired 39,029 shares of Zymeworks stock. The stock was purchased at an average cost of $14.01 per share, for a total transaction of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The stock was bought at an average price of $13.39 per share, with a total value of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc bought 204,098 shares of Zymeworks stock. The stock was bought at an average price of $13.13 per share, with a total value of $2,679,806.74.
- On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The stock was bought at an average price of $14.07 per share, with a total value of $295,765.47.
- On Thursday, January 2nd, Ecor1 Capital, Llc bought 157,880 shares of Zymeworks stock. The stock was bought at an average price of $14.78 per share, with a total value of $2,333,466.40.
- On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The shares were acquired at an average price of $14.47 per share, with a total value of $853,556.36.
Zymeworks Price Performance
NYSE ZYME opened at $12.72 on Friday. The company has a 50 day simple moving average of $13.72 and a 200-day simple moving average of $13.68. The firm has a market capitalization of $885.02 million, a price-to-earnings ratio of -8.48 and a beta of 1.13. Zymeworks Inc. has a 52-week low of $7.97 and a 52-week high of $17.70.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on ZYME
Institutional Trading of Zymeworks
A number of hedge funds have recently made changes to their positions in ZYME. Sterling Capital Management LLC raised its position in Zymeworks by 781.5% during the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company’s stock valued at $25,000 after acquiring an additional 1,524 shares in the last quarter. AlphaQuest LLC raised its position in Zymeworks by 480.2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company’s stock valued at $41,000 after acquiring an additional 2,324 shares in the last quarter. FMR LLC raised its position in Zymeworks by 84.2% during the third quarter. FMR LLC now owns 3,336 shares of the company’s stock valued at $42,000 after acquiring an additional 1,525 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Zymeworks during the fourth quarter valued at approximately $108,000. Finally, Tower Research Capital LLC TRC raised its position in Zymeworks by 343.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company’s stock valued at $142,000 after acquiring an additional 7,518 shares in the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.
About Zymeworks
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Stories
- Five stocks we like better than Zymeworks
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- FedEx Delivers Another Crushing Blow to Its Stock Price
- What is the S&P 500 and How It is Distinct from Other Indexes
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- What is a Special Dividend?
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.